This is what analysts have to say about Corcept Therapeutics Incorporated (NASDAQ:CORT) after last week.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Logo
Investors sentiment decreased to 1.11 in 2018 Q3. Its down 0.07, from 1.18 in 2018Q2. It fall, as 29 investors sold Corcept Therapeutics Incorporated shares while 52 reduced holdings. 24 funds opened positions while 66 raised stakes. 86.70 million shares or 1.74% more from 85.22 million shares in 2018Q2 were reported.
Deutsche Savings Bank Ag stated it has 326,145 shares. Swiss Commercial Bank holds 0% or 178,900 shares in its portfolio. Fifth Third National Bank reported 41,452 shares stake. Alliancebernstein Limited Partnership holds 0% or 259,270 shares. Employees Retirement Association Of Colorado reported 12,525 shares stake. Renaissance Technologies Ltd Liability holds 0.06% or 4.42M shares. Fund reported 540,818 shares. Crow Point Prtn Limited Liability Corporation holds 23,488 shares or 0.06% of its portfolio. The Illinois-based Ubs Asset Americas has invested 0% in Corcept Therapeutics Incorporated (NASDAQ:CORT). D E Shaw Inc stated it has 129,290 shares or 0% of all its holdings. Tci Wealth Advsrs holds 0% or 75 shares in its portfolio. State Common Retirement Fund accumulated 108,600 shares or 0% of the stock. Quantitative Invest holds 25,000 shares or 0.01% of its portfolio. Commercial Bank Of Montreal Can owns 3,629 shares. Barclays Public Limited Co owns 123,887 shares.

Since August 14, 2018, it had 4 buys, and 6 selling transactions for $775,497 activity. FISHMAN ROBERT S also sold $109,887 worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) on Wednesday, November 7. Robb Gary Charles had sold 25,000 shares worth $475,153. Maduck Sean sold 60,000 shares worth $1.14M. $4.13M worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) was sold by BELANOFF JOSEPH K on Wednesday, December 12.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Ratings Coverage

Among 2 analysts covering Corcept Therapeutics (NASDAQ:CORT), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corcept Therapeutics had 3 analyst reports since August 13, 2018 according to SRatingsIntel. The stock has “Overweight” rating by Cantor Fitzgerald on Wednesday, December 12. On Monday, August 13 the stock rating was maintained by FBR Capital with “Buy”. Below is a list of Corcept Therapeutics Incorporated (NASDAQ:CORT) latest ratings and price target changes.

12/12/2018 Broker: Cantor Fitzgerald Old Rating: Neutral New Rating: Overweight Old Target: $17 New Target: $29 Upgrade
23/08/2018 Broker: Cantor Fitzgerald Rating: Neutral New Target: $17 Initiates Coverage On
13/08/2018 Broker: FBR Capital Old Rating: Buy New Rating: Buy Old Target: $30 New Target: $22 Maintain

The stock increased 9.46% or $1.32 during the last trading session, reaching $15.28. About 1.48 million shares traded or 4.69% up from the average. Corcept Therapeutics Incorporated (NASDAQ:CORT) has declined 21.43% since January 14, 2018 and is downtrending. It has underperformed by 21.43% the S&P500.

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company has market cap of $1.76 billion. It offers Korlym tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It has a 12.8 P/E ratio. The firm is also developing Korlym in combination with eribulin, which is in Phase I/II clinical trial to treat patients with metastatic triple-negative breast cancer; Korlym in combination with drug Abraxane that is in Phase II clinical trial to treat patients with triple-negative breast cancer; and Korlym combined with the androgen deprivation agent enzalutamide, which is in Phase II clinical trial to treat patients with metastatic castration-resistant prostate cancer.

Another recent and important Corcept Therapeutics Incorporated (NASDAQ:CORT) news was published by Nasdaq.com which published an article titled: “Corcept (CORT) Earnings and Revenues Miss Estimates in Q2 – Nasdaq” on August 10, 2018.

Corcept Therapeutics Incorporated (NASDAQ:CORT) Institutional Positions Chart

(adsbygoogle = window.adsbygoogle || []).push({});

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.